肺癌
肺癌是最常見的肺原發性惡性腫瘤，目前全世界每年發病人數第二、死亡人數第二。據世界衛生組織國際癌癥研究署（IARC）發布的2020年全球癌癥負擔數據，2020年全世界新增肺癌病例220萬（僅次于乳腺癌），新增肺癌死亡病例180萬（遠超其他癌癥）。非小細胞肺癌（NSCLC）約占所有肺癌病例的85%，其5年生存率僅為20%左右。
近年來，肺癌藥物研發進展迅猛，目前全球已上市生物藥數量達102種，聚焦于EGFR、ALK等靶點的靶向藥物和PD-1/PD-L1免疫療法、抗體偶聯藥物（ADC）。
- 在靶向治療方面，針對EGFR、ALK、ROS1等特定基因突變的藥物不斷涌現。例如，針對EGFR突變的非小細胞肺癌，已經開發出多種代的TKI（酪氨酸激酶抑制劑），如第一代的吉非替尼、第二代的阿法替尼以及第三代的奧希替尼等。此外，針對EGFR外顯子20插入突變的NSCLC患者，amivantamab聯合化療已經顯示出顯著的療效。
- 免疫治療方面，PD-1/PD-L1抑制劑如帕博利珠單抗（pembrolizumab）、納武單抗（nivolumab）等已經在肺癌治療中取得顯著進展。例如，PAPILLON研究顯示，amivantamab聯合化療可顯著延長攜帶EGFR外顯子20插入突變晚期NSCLC的中位PFS6。此外，針對PD-L1表達水平較高的非小細胞肺癌患者，免疫治療已經成為新的標準治療選項。
- 抗體藥物偶聯物（ADC）是近年來肺癌治療領域的新興研究方向。ADC藥物通過將抗體與化療藥物或放射性物質結合，提高治療的靶向性和效果。例如，針對HER2突變的非小細胞肺癌，新型ADC藥物如trastuzumab deruxtecan（T-DXd）已經顯示出較好的療效。
肺癌藥物靶點
- ALB
- AXL
- BSG
- BTLA
- CA9
- CCR8
- CD27
- CD274
- CD276
- CD28
- CD3E
- CD40
- CD44
- CD47
- CD86
- CEACAM5
- CEACAM6
- CHEK1
- CHI3L1
- CLDN6
- COL18A1
- CSF1R
- CSF2
- CSF3R
- CTAG1A
- CTLA4
- DLK1
- DLL3
- DNA2
- DRD4
- EGFR
- ENG
- ENTPD1
- EpCAM
- EphA2
- EpoR
- ERBB2
- ERBB3
- FCY1
- FGFR3
- FLT1
- FLT3
- FN1
- FOLH1
- FOLR1
- GDF15
- GPC2
- GPC3
- HAVCR2
- HGF
- ICOS
- IFNAR1
- IGF1R
- IL10RA
- IL12A
- IL12RB1
- IL15RA
- IL1B
- IL2
- IL2RA
- IL2RB
- IL2RG
- IL4R
- IL6
- ITGA5
- KDR
- KIT
- KLRC1
- LAG3
- LILRB2
- LILRB4
- MAGEA4
- MELTF
- MET
- MSLN
- MUC1
- NCAM1
- NCL
- NECTIN4
- NT5E
- PDCD1
- PDGFRB
- PGF
- PTK7
- PVRIG
- ROR1
- SIRPA
- SLC34A2
- STING1
- TACSTD2
- TF
- TGFB1
- TGFB2
- TIGIT
- TLR8
- TNF
- TNFRSF10B
- TNFRSF18
- TNFRSF1A
- TNFRSF1B
- TNFRSF4
- TNFSF4
- TNFSF9
- TOP1
- TPBG
- VEGFA
- VSIR
- VTCN1
肺癌藥物靶點相關產品推薦
● 靶點蛋白
CSB-MP619964HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP007479HU
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
CSB-MP878942HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
CSB-MP006163HU1
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml
CSB-MP007763HU
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized MET at 2 μg/ml can bind Anti-MET recombinant antibody, the EC50 is 2.379-3.094.
CSB-MP675446HU
FACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155.
CSB-MP023997HU1
Measured by its binding ability in a functional ELISA. Immobilized TNFSF9 at 2 μg/ml can bind TNFRSF9（CSB-MP023984HU1）, the EC50 is 2.671-3.702 ng/mL.
| 產品名稱 | 貨號 | 靶點 | 來源 | 蛋白標簽 |
|---|---|---|---|---|
| Recombinant Human Basigin (BSG), partial (Active) | CSB-MP002831HU1 | BSG | Mammalian cell | C-terminal hFc-tagged |
| Recombinant Human B- and T-lymphocyte attenuator (BTLA), partial (Active) | CSB-MP773799HU | BTLA | Mammalian cell | C-terminal hFc-Myc-tagged |
| Recombinant Human B- and T-lymphocyte attenuator (BTLA), partial (Active) | CSB-MP773799HU1 | BTLA | Mammalian cell | C-terminal 10xHis-tagged |
| Recombinant Human C-C chemokine receptor type 8 (CCR8)-VLPs (Active) | CSB-MP004847HU | CCR8 | Mammalian cell | C-terminal 10xHis-tagged (This tag can be tested only under denaturing conditions) |
| Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial (Active) | CSB-MP878942HU1 | CD274 | Mammalian cell | C-terminal hFc-tagged |
| Recombinant Human CD276 antigen (CD276), partial (Active) | CSB-MP733578HU | CD276 | Mammalian cell | C-terminal hFc-Myc-tagged |
| Recombinant Human Tumor necrosis factor receptor superfamily member 5 (CD40), partial (Active) | CSB-MP004936HU1 | CD40 | Mammalian cell | C-terminal hFc-tagged |
| Recombinant Human CD44 antigen (CD44), partial (Active) | CSB-MP004938HU(F1) | CD44 | Mammalian cell | C-terminal hFc-tagged |
| Recombinant Human CD44 antigen (CD44), partial, Biotinylated (Active) | CSB-MP004938HU(F1)j1-B | CD44 | Mammalian cell | C-terminal mFc-Avi-tagged |
| Recombinant Macaca fascicularis CD44 antigen (CD44), partial (Active) | CSB-MP4290MOV | CD44 | Mammalian cell | C-terminal 10xHis-tagged |
| Recombinant Human Leukocyte surface antigen CD47 (CD47), partial (Active) | CSB-MP004940HU | CD47 | Mammalian cell | C-terminal hFc-tagged |
| Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) (E398K) (Active) | CSB-MP005165HU | CEACAM5 | Mammalian cell | C-terminal?10xHis-tagged |
| Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) (Active) | CSB-MP005166HU | CEACAM6 | Mammalian cell | C-terminal 10xHis-tagged |
| Recombinant Human Claudin-6 (CLDN6)-VLPs (Active) | CSB-MP005508HU(A4) | CLDN6 | Mammalian cell | C-terminal 10xHis-tagged (This tag can be tested only under denaturing conditions) |
| Recombinant Human Claudin-6 (CLDN6)-VLPs, Fluorescent (Active) | CSB-MP005508HU(A4)f4 | CLDN6 | Mammalian cell | C-terminal GFP-tagged (This tag can be tested only under denaturing conditions) |
| Recombinant Human Cytotoxic T-lymphocyte protein 4 (CTLA4), partial (Active) | CSB-MP006163HU1 | CTLA4 | Mammalian cell | C-terminal hFc-tagged |
| Recombinant Human Delta-like protein 3 (DLL3), partial (Active) | CSB-MP882142HU | DLL3 | Mammalian cell | C-terminal 6xHis-tagged |
| Recombinant Macaca fascicularis Delta-like protein 3 (DLL3), partial (Active) | CSB-MP3536MOV | DLL3 | Mammalian cell | C-terminal 6xHis-tagged |
| Recombinant Human Epidermal growth factor receptor (EGFR), partial (Active) | CSB-MP007479HU | EGFR | Mammalian cell | N-terminal 10xHis-tagged and C-terminal Myc-tagged |
| Recombinant Human Receptor tyrosine-protein kinase erbB-2 (ERBB2), partial (Active) | CSB-MP007763HU | ERBB2 | Mammalian cell | C-terminal 6xHis-tagged |
● 細胞株
● 抗體
CSB-RA292372A0HU
Overlay Peak curve showing Hela cells surface stained with CSB-RA878942MA1HU (red line) at 1:100.
CSB-RA006163MA1HU
Overlay Peak curve showing JK cells surface stained with CSB-RA006163MA1HU (red line) at 1:50.
CSB-RA159341A0HU
Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
CSB-RA983271A0HU
Overlay histogram showing Hela cells stained with CSB-RA983271A0HU (red line) at 1:50.
| 產品名稱 | 貨號 | 靶點 | 反應種屬 | 應用范圍 |
|---|---|---|---|---|
| ALB Recombinant Monoclonal Antibody | CSB-RA264109A0HU | ALB | Human | ELISA, FC |
| BTLA Recombinant Monoclonal Antibody | CSB-RA773799MA1HU | BTLA | Human | ELISA, FC |
| CA9 Recombinant Monoclonal Antibody | CSB-RA614990A0HU | CA9 | Human | ELISA, IHC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847A1HU | CCR8 | Human | FC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA3HU | CCR8 | Human | FC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA2HU | CCR8 | Human | FC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA4HU | CCR8 | Human | FC |
| CD27 Recombinant Monoclonal Antibody | CSB-RA953976A0HU | CD27 | Human | ELISA, WB |
| CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
| CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
| CD3E Recombinant Monoclonal Antibody | CSB-RA004931MA1HU | CD3E | Human | ELISA, FC |
| CD40 Recombinant Monoclonal Antibody | CSB-RA004936MA1HU | CD40 | Human | ELISA, IF, FC |
| CD44 Recombinant Monoclonal Antibody | CSB-RA004938A0HU | CD44 | Human | ELISA, WB, IHC |
| CD44 Recombinant Monoclonal Antibody | CSB-RA292372A0HU | CD44 | Human | ELISA, WB, IHC, IF, FC |
| CD44 Recombinant Monoclonal Antibody | CSB-RA004938MA1HU | CD44 | Human | ELISA, FC |
| CD47 Recombinant Monoclonal Antibody | CSB-RA802124A0HU | CD47 | Human | ELISA, WB, IHC, IF |
| CD86 Recombinant Monoclonal Antibody | CSB-RA004965A0HU | CD86 | Human | ELISA, WB |
| CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
| CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
| CHEK1 Recombinant Monoclonal Antibody | CSB-RA176809A0HU | CHEK1 | Human | ELISA, WB, IHC, IF |
● ELISA試劑盒
| 產品名稱 | 貨號 | 靶點 | 檢測范圍 | 靈敏度 |
|---|---|---|---|---|
| 牛白蛋白(ALB)酶聯免疫試劑盒 | CSB-E08664b | ALB | 0.313 μg/mL-80 μg/mL | 0.148 μg/mL |
| 小鼠白蛋白酶聯免疫試劑盒 | CSB-E13878m | ALB | 0.781 μg/mL-200 μg/mL | 0.110 μg/mL |
| 犬白蛋白(Alb)酶聯免疫試劑盒 | CSB-E15757c | ALB | 0.273 μg/mL-35 μg/mL | 0.266 μg/mL |
| 綿羊白蛋白酶聯免疫試劑盒 | CSB-E15839Sh | ALB | 350 μg/mL-21.88 μg/mL | 5.5 μg/mL |
| 馬白蛋白酶聯免疫試劑盒 | CSB-E16205Hs | ALB | 1.25 μg/mL-80 μg/mL | 1.247 μg/mL |
| 豬白蛋白酶聯免疫試劑盒 | CSB-E16207p | ALB | 0.03 μg/mL-7000 μg/mL | 0.03 μg/mL |
| 山羊白蛋白(Alb)酶聯免疫試劑盒 | CSB-E15758G | ALB | 0.17 μg/mL-350 μg/mL | 0.17 μg/mL |
| 豚鼠白蛋白(ALB)酶聯免疫試劑盒 | CSB-E15765Gp | ALB | 0.156 μg/mL-10 μg/mL | 0.09 μg/mL |
| 兔白蛋白酶聯免疫試劑盒 | CSB-E16204Rb | ALB | 0.273 μg/mL-70 μg/mL | 0.117 μg/mL |
| 人酪氨酸蛋白激酶受體UFO(AXL)酶聯免疫試劑盒 | CSB-EL002476HU | AXL | 31.25 pg/mL-2000 pg/mL | 7.81 pg/mL |
| 小鼠酪氨酸蛋白激酶受體UFO(AXL)酶聯免疫試劑盒 | CSB-EL002476MO | AXL | 31.25 pg/ml-2000 pg/ml | 7.81 pg/ml |
| 人CD147分子(CD147)酶聯免疫試劑盒 | CSB-E12994h | BSG | 12.5 pg/mL-800 pg/mL | 3.12 pg/mL |
| 人B和T淋巴細胞衰減因子(BTLA)酶聯免疫試劑盒 | CSB-EL002868HU | BTLA | 0.45 ng/mL-30 ng/mL | 0.11 ng/mL |
| 小鼠B和T淋巴細胞衰減因子(BTLA)酶聯免疫試劑盒 | CSB-EL002868MO | BTLA | 0.625 ng/mL-40 ng/mL | 0.156 ng/mL |
| 人碳酸酐酶9(CA9)酶聯免疫試劑盒 | CSB-E13266h | CA9 | 31.25 pg/mL-2000 pg/mL | 7.81 pg/mL |
| 人程序性死亡因子配體1(PD-L1/CD274)酶聯免疫試劑盒 | CSB-E13644h | CD274 | 15.6 pg/mL-1000 pg/mL | 3.9 pg/mL |
| 小鼠程序性細胞死亡配體1(CD274) ELISA Kit | CSB-EL004911MO | CD274 | 31.25 pg/mL-2000 pg/mL | 7.81 pg/mL |
| 人可溶性CD276分子(sCD276/sB7-H3)酶聯免疫試劑盒 | CSB-E14285h | CD276 | 3.12 ng/mL-200 ng/mL | 0.78 ng/mL |
| 人可溶性CD28(sCD28)酶聯免疫試劑盒 | CSB-E09296h | CD28 | 0.625 ng/mL-40 ng/mL | 0.156 ng/mL |
| 小鼠腫瘤壞死因子受體超家族成員5(CD40)酶聯免疫試劑盒 | CSB-EL004936MO | CD40 | Request Information | Request Information |
